PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25912549-0 2015 Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor. Paclitaxel 58-68 cyclin dependent kinase inhibitor 1A Homo sapiens 28-35 25912549-6 2015 In A375P cells, paclitaxel treatment resulted in a marked emergence of apoptotic cells after mitotic arrest, concomitant with a remarkable induction of p21(Cip1). Paclitaxel 16-26 cyclin dependent kinase inhibitor 1A Homo sapiens 152-155 25912549-6 2015 In A375P cells, paclitaxel treatment resulted in a marked emergence of apoptotic cells after mitotic arrest, concomitant with a remarkable induction of p21(Cip1). Paclitaxel 16-26 cyclin dependent kinase inhibitor 1A Homo sapiens 156-160 25912549-7 2015 However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel. Paclitaxel 9-19 cyclin dependent kinase inhibitor 1A Homo sapiens 60-63 25912549-7 2015 However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel. Paclitaxel 9-19 cyclin dependent kinase inhibitor 1A Homo sapiens 64-68 25912549-7 2015 However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel. Paclitaxel 129-139 cyclin dependent kinase inhibitor 1A Homo sapiens 60-63 25912549-7 2015 However, paclitaxel only moderately increased the levels of p21(Cip1) in A375P/Mdr cells, which exhibited a strong resistance to paclitaxel. Paclitaxel 129-139 cyclin dependent kinase inhibitor 1A Homo sapiens 64-68 25912549-8 2015 The p21(Cip1) overexpression partially conferred paclitaxel sensitivity to A375P/Mdr cells. Paclitaxel 49-59 cyclin dependent kinase inhibitor 1A Homo sapiens 4-7 25912549-8 2015 The p21(Cip1) overexpression partially conferred paclitaxel sensitivity to A375P/Mdr cells. Paclitaxel 49-59 cyclin dependent kinase inhibitor 1A Homo sapiens 8-12 25912549-10 2015 Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors. Paclitaxel 43-53 cyclin dependent kinase inhibitor 1A Homo sapiens 128-131 25912549-10 2015 Taken together, these results suggest that paclitaxel may be an effective anticancer agent through regulating the expression of p21(Cip1) for the treatment of BRAF mutant melanoma cells resistant to BRAF inhibitors. Paclitaxel 43-53 cyclin dependent kinase inhibitor 1A Homo sapiens 132-136 26146988-7 2015 In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells. Paclitaxel 58-68 cyclin dependent kinase inhibitor 1A Homo sapiens 294-297 26146988-7 2015 In addition, CDK5 knockdown alone and in combination with paclitaxel induced G1 cell cycle arrest and caspase 3 dependent apoptotic cell death associated with post-translational upregulation and nuclear translocation of TP53 and p27(Kip1) as well as TP53-dependent transcriptional induction of p21(Cip1) in wild type TP53 cancer cells. Paclitaxel 58-68 cyclin dependent kinase inhibitor 1A Homo sapiens 298-302 25647149-13 2015 The decreased responsiveness to paclitaxel observed in 10CA1a tumor cells was likely due, in part, to activation of the Akt signaling pathway and a high expression of wild-type p53 with lack of p21Waf1/Cip1. Paclitaxel 32-42 cyclin dependent kinase inhibitor 1A Homo sapiens 202-206 24858045-8 2015 Moreover, p21 is dramatically stabilized in mitotic tumor cells upon treatment with mitotic agents like paclitaxel or mitotic kinase inhibitors. Paclitaxel 104-114 cyclin dependent kinase inhibitor 1A Homo sapiens 10-13 20944098-7 2010 Phosphorylation of p21Cip/Waf1, but not change in total levels, correlated with the chemosensitizing effect of Akt inhibition to paclitaxel. Paclitaxel 129-139 cyclin dependent kinase inhibitor 1A Homo sapiens 26-30 23023313-0 2012 Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Paclitaxel 0-5 cyclin dependent kinase inhibitor 1A Homo sapiens 112-124 23023313-7 2012 The inhibitory effects of taxol on cell growth and apoptosis induced by taxol were also associated with the downregulation of Wee1 kinase expression and a marked induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1. Paclitaxel 26-31 cyclin dependent kinase inhibitor 1A Homo sapiens 261-265 23023313-7 2012 The inhibitory effects of taxol on cell growth and apoptosis induced by taxol were also associated with the downregulation of Wee1 kinase expression and a marked induction in the activity of the cyclin-dependent kinase inhibitor, p21WAF/CIP1. Paclitaxel 72-77 cyclin dependent kinase inhibitor 1A Homo sapiens 261-265 23023313-8 2012 Furthermore, taxol elevated p21 promoter activity in both cell lines. Paclitaxel 13-18 cyclin dependent kinase inhibitor 1A Homo sapiens 28-31 23023313-9 2012 These findings suggest that taxol-induced G2/M arrest and apoptosis in human breast carcinoma cells is mediated through the ER- and p53-independent upregulation of p21. Paclitaxel 40-45 cyclin dependent kinase inhibitor 1A Homo sapiens 188-191 22194993-7 2011 In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21(WAF1/Cip1) by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53. Paclitaxel 166-176 cyclin dependent kinase inhibitor 1A Homo sapiens 152-156 22194993-7 2011 In contrast to SAHA, which was substantially less effective in sensitizing cells to paclitaxel-induced apoptosis, ST2782 prevented up-regulation of p21(WAF1/Cip1) by paclitaxel, which has a protective role in response to taxanes, and caused p53 down-regulation, acetylation and mitochondrial localization of acetylated p53. Paclitaxel 166-176 cyclin dependent kinase inhibitor 1A Homo sapiens 157-161 20624405-7 2010 SIGNIFICANCE: our study demonstrates that the short-carbon chain C(2)-ceramide can effectively sensitize PTX-induced senescence of H1299 cells via both p21(waf1/cip1)- and p16(ink4)-independent pathways. Paclitaxel 105-108 cyclin dependent kinase inhibitor 1A Homo sapiens 152-165 26775347-0 2015 Cytoplasmic p21 is responsible for paclitaxel resistance in ovarian cancer A2780 cells. Paclitaxel 35-45 cyclin dependent kinase inhibitor 1A Homo sapiens 12-15 26775347-2 2015 This study was conducted to investigate the role of p21 in the paclitaxel (PTX) resistance of ovarian cancer. Paclitaxel 63-73 cyclin dependent kinase inhibitor 1A Homo sapiens 52-55 26775347-2 2015 This study was conducted to investigate the role of p21 in the paclitaxel (PTX) resistance of ovarian cancer. Paclitaxel 75-78 cyclin dependent kinase inhibitor 1A Homo sapiens 52-55 26775347-5 2015 RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity. Paclitaxel 139-142 cyclin dependent kinase inhibitor 1A Homo sapiens 22-25 26775347-5 2015 RESULTS: Induction of p21 translocation into the cytoplasm via constitutively active Akt2 transfection in A2780 enhanced the resistance to PTX, while inhibition of p21 translocation into the cytoplasm via Akt2 shRNA trans- fection in A2780 cells significantly increased PTX treatment sensitivity. Paclitaxel 270-273 cyclin dependent kinase inhibitor 1A Homo sapiens 22-25 26775347-6 2015 Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis. Paclitaxel 127-130 cyclin dependent kinase inhibitor 1A Homo sapiens 38-41 26775347-6 2015 Furthermore, knockdown of cytoplasmic p21 by direct p21 siRNA transfection in Akt2 overexpressed A2780 cells notably increased PTX-induced apoptosis. Paclitaxel 127-130 cyclin dependent kinase inhibitor 1A Homo sapiens 52-55 26775347-7 2015 CONCLUSION: Cytoplasmic p21 may represent a potential therapeutic target for ovarian tumors that are resistant to PTX treatment. Paclitaxel 114-117 cyclin dependent kinase inhibitor 1A Homo sapiens 24-27 21822799-3 2011 Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells. Paclitaxel 219-229 cyclin dependent kinase inhibitor 1A Homo sapiens 90-93 21822799-3 2011 Ectopic expression of the dominant negative Cdk2 (Cdk2-dn) and a specific Cdk2 inhibitor, p21( WAF1/CIP1 ), effectively suppresses the loss of MMP, the release of cytochrome c, and subsequent activation of caspase-3 in paclitaxel-treated cells. Paclitaxel 219-229 cyclin dependent kinase inhibitor 1A Homo sapiens 95-104 18806740-3 2008 RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1. Paclitaxel 21-26 cyclin dependent kinase inhibitor 1A Homo sapiens 170-173 20018861-0 2010 Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. Paclitaxel 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 23-26 20018861-0 2010 Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. Paclitaxel 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 27-31 20018861-0 2010 Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment. Paclitaxel 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 32-36 20018861-6 2010 Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel. Paclitaxel 180-190 cyclin dependent kinase inhibitor 1A Homo sapiens 46-49 20018861-6 2010 Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel. Paclitaxel 180-190 cyclin dependent kinase inhibitor 1A Homo sapiens 50-54 20018861-6 2010 Finally, we demonstrate that hGTSE-1 mediated-p21(CIP1/WAF1) stabilization is clearly involved in the ability of cells to counteract cytotoxicity induced by the microtubule poison paclitaxel. Paclitaxel 180-190 cyclin dependent kinase inhibitor 1A Homo sapiens 55-59 19372587-2 2009 Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1). Paclitaxel 48-53 cyclin dependent kinase inhibitor 1A Homo sapiens 130-133 19372587-2 2009 Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21(Cip1). Paclitaxel 48-53 cyclin dependent kinase inhibitor 1A Homo sapiens 134-138 19372587-7 2009 Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells. Paclitaxel 141-146 cyclin dependent kinase inhibitor 1A Homo sapiens 118-121 19372587-7 2009 Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21(Cip1) that confers Taxol resistance of breast cancer cells. Paclitaxel 141-146 cyclin dependent kinase inhibitor 1A Homo sapiens 122-126 18806740-3 2008 RESULTS: Low dose of Taxol that cause apoptosis (25 nM) enhanced Rb protein phosphorylation, decreased the expression of cyclin-dependent kinase inhibitors p27(KIP1) and p21(WAF1) , and potentiated the accumulation of phosphorylated p53 and of the prolyl isomerase Pin1. Paclitaxel 21-26 cyclin dependent kinase inhibitor 1A Homo sapiens 174-178 15467449-0 2004 The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Paclitaxel 60-70 cyclin dependent kinase inhibitor 1A Homo sapiens 38-41 16331265-0 2006 Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Paclitaxel 68-78 cyclin dependent kinase inhibitor 1A Homo sapiens 148-152 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 169-172 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 173-177 16432835-0 2006 A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Paclitaxel 64-74 cyclin dependent kinase inhibitor 1A Homo sapiens 2-5 16432835-0 2006 A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Paclitaxel 64-74 cyclin dependent kinase inhibitor 1A Homo sapiens 6-10 16432835-10 2006 Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant. Paclitaxel 78-88 cyclin dependent kinase inhibitor 1A Homo sapiens 22-25 16432835-10 2006 Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant. Paclitaxel 78-88 cyclin dependent kinase inhibitor 1A Homo sapiens 26-30 16432835-10 2006 Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant. Paclitaxel 78-88 cyclin dependent kinase inhibitor 1A Homo sapiens 141-144 16432835-10 2006 Our data suggest that p21/WAF1 inactivation may confer a strong resistance to paclitaxel in noncancerous breast epithelial cells harboring a p21/WAF1 mutant. Paclitaxel 78-88 cyclin dependent kinase inhibitor 1A Homo sapiens 145-149 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 178-182 15467449-0 2004 The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Paclitaxel 60-70 cyclin dependent kinase inhibitor 1A Homo sapiens 42-46 15467449-0 2004 The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells. Paclitaxel 60-70 cyclin dependent kinase inhibitor 1A Homo sapiens 47-51 15467449-1 2004 The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat). Paclitaxel 94-104 cyclin dependent kinase inhibitor 1A Homo sapiens 76-79 15467449-1 2004 The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat). Paclitaxel 94-104 cyclin dependent kinase inhibitor 1A Homo sapiens 80-84 15467449-1 2004 The functional significance of the cyclin-dependent kinase inhibitor (CDKI) p21(Cip1/WAF1) in paclitaxel-mediated lethality was examined in p53-null human leukemia cells (U937 and Jurkat). Paclitaxel 94-104 cyclin dependent kinase inhibitor 1A Homo sapiens 85-89 15467449-3 2004 Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential. Paclitaxel 96-106 cyclin dependent kinase inhibitor 1A Homo sapiens 53-56 15467449-3 2004 Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential. Paclitaxel 96-106 cyclin dependent kinase inhibitor 1A Homo sapiens 57-61 15467449-3 2004 Nevertheless, stable expression of U937 cells with a p21(Cip1/WAF1) antisense construct blocked paclitaxel-induced G(2)M arrest and increased mitochondrial injury, caspase activation, apoptosis, and loss of clonogenic potential. Paclitaxel 96-106 cyclin dependent kinase inhibitor 1A Homo sapiens 62-66 15467449-4 2004 Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis. Paclitaxel 150-160 cyclin dependent kinase inhibitor 1A Homo sapiens 54-57 15467449-4 2004 Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis. Paclitaxel 150-160 cyclin dependent kinase inhibitor 1A Homo sapiens 58-62 15467449-4 2004 Consistent with these results, enforced expression of p21(Cip1/WAF1) in Jurkat cells increased the percentage of cells arrested in G2M and attenuated paclitaxel-mediated mitochondrial injury and apoptosis. Paclitaxel 150-160 cyclin dependent kinase inhibitor 1A Homo sapiens 63-67 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 63-73 cyclin dependent kinase inhibitor 1A Homo sapiens 37-40 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 63-73 cyclin dependent kinase inhibitor 1A Homo sapiens 41-45 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 63-73 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 116-126 cyclin dependent kinase inhibitor 1A Homo sapiens 37-40 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 116-126 cyclin dependent kinase inhibitor 1A Homo sapiens 41-45 15467449-5 2004 Unexpectedly, enforced expression of p21(Cip1/WAF1) diminished paclitaxel-mediated inactivation of ERK, and reduced paclitaxel-induced activation of JNK as well as Bcl-2 phosphorylation. Paclitaxel 116-126 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 38-41 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 42-46 15467449-6 2004 Together, these findings suggest that p21(Cip1/WAF1) partially protects p53-null human leukemia cells from paclitaxel-mediated lethality, and raise the possibility that p21(Cip1/WAF1)-associated perturbations in signal transduction pathways as well as Bcl-2 phosphorylation status may play a role in this phenomenon. Paclitaxel 107-117 cyclin dependent kinase inhibitor 1A Homo sapiens 47-51 12684432-7 2003 The cell cycle regulator p53 and its target genes p21(waf1/cip1) and BAX were induced in SCC-61 cells treated with 2 Gy, Paclitaxel, or in combination, but not in SQ-20B cells. Paclitaxel 121-131 cyclin dependent kinase inhibitor 1A Homo sapiens 50-63 14985451-7 2004 The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. Paclitaxel 178-188 cyclin dependent kinase inhibitor 1A Homo sapiens 44-50 12574211-0 2003 p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. Paclitaxel 62-72 cyclin dependent kinase inhibitor 1A Homo sapiens 0-16 12432259-12 2002 In summary, only low concentrations of FL can induce p21, and, in turn, only p21-sensitive cells are protected from PTX. Paclitaxel 116-119 cyclin dependent kinase inhibitor 1A Homo sapiens 77-80 12530065-0 2002 Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Paclitaxel 83-93 cyclin dependent kinase inhibitor 1A Homo sapiens 30-42 12530065-3 2002 Biochemical examination also revealed that 5-FU inhibited expression of p21WAF1/CIP1 that may contribute to paclitaxel cytotoxicity. Paclitaxel 108-118 cyclin dependent kinase inhibitor 1A Homo sapiens 80-84 12530065-6 2002 RESULTS: Tumor cells transfected with antisense p53 or p21WAF1/CIP1 exhibited a significant increase in their sensitivity to paclitaxel. Paclitaxel 125-135 cyclin dependent kinase inhibitor 1A Homo sapiens 63-67 12530065-7 2002 The reduced protein levels of p53 and p21WAF1/CIP1 were also found to abrogate the inhibitory effects of 5-FU on paclitaxel-induced mitotic arrest and apoptosis. Paclitaxel 113-123 cyclin dependent kinase inhibitor 1A Homo sapiens 46-50 12530065-8 2002 CONCLUSION: These findings suggest that the status of p53 and p21WAF1/CIP1 might play an important role in tumor cell susceptibility to paclitaxel and its combination with other drugs such as 5-FU. Paclitaxel 136-146 cyclin dependent kinase inhibitor 1A Homo sapiens 70-74 12384528-5 2002 Herceptin plus Taxol treatment led to higher levels of p34(Cdc2) kinase activity and apoptosis in ErbB2-overexpressing breast cancer cells, which is likely attributable to inhibition of Cdc2-Tyr-15 phosphorylation and p21(Cip1) expression. Paclitaxel 15-20 cyclin dependent kinase inhibitor 1A Homo sapiens 222-226 12384528-8 2002 Thus, Herceptin treatment of ErbB2-overexpressing cells can inhibit ErbB2-mediated Cdc2-Tyr-15 phosphorylation and p21(Cip1) up-regulation, which allows effective p34(Cdc2) activation and induction of apoptosis upon Taxol treatment. Paclitaxel 216-221 cyclin dependent kinase inhibitor 1A Homo sapiens 119-123 12432259-0 2002 Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel. Paclitaxel 92-102 cyclin dependent kinase inhibitor 1A Homo sapiens 67-70 11593424-7 2001 Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Paclitaxel 80-90 cyclin dependent kinase inhibitor 1A Homo sapiens 25-28 11593424-7 2001 Induction of p16(Ink4a), p21(Waf1), or p27(Kip1) conferred strong resistance to paclitaxel- or cisplatin-mediated cytotoxicity on the CKI-responsive A431 cells but not on the CKI-unresponsive SiHa cells. Paclitaxel 80-90 cyclin dependent kinase inhibitor 1A Homo sapiens 29-33 9844631-0 1998 Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Paclitaxel 31-36 cyclin dependent kinase inhibitor 1A Homo sapiens 74-81 11034077-0 2000 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Paclitaxel 152-162 cyclin dependent kinase inhibitor 1A Homo sapiens 117-121 11034077-0 2000 The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Paclitaxel 152-162 cyclin dependent kinase inhibitor 1A Homo sapiens 122-126 11034077-3 2000 Here, we demonstrate that phosphatidylinositol 3-kinase (PI3K) and its downstream targets serine/threonine kinases AKT1 and AKT2 (AKT), are required for the full induction of p21 in A2780 cells treated with cisplatin or paclitaxel. Paclitaxel 220-230 cyclin dependent kinase inhibitor 1A Homo sapiens 175-178 11034077-6 2000 Experiments with additional ovarian carcinoma cell lines revealed that PI3K is involved in the expression of p21 induced by cisplatin or paclitaxel in OVCAR-10 cells, which have wild-type p53, but not in OVCAR-5 cells, which lack functional p53. Paclitaxel 137-147 cyclin dependent kinase inhibitor 1A Homo sapiens 109-112 11045764-12 2000 Clonogenic assays showed that Ad5CMV-p21 reduced the sensitivity of MDA-MB-231 to VP-16 and paclitaxel. Paclitaxel 92-102 cyclin dependent kinase inhibitor 1A Homo sapiens 37-40 10347252-0 1999 Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Paclitaxel 75-85 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 10347252-1 1999 We examined the effect of overexpression of p21(waf1) on cytotoxicity of paclitaxel, a microtubule stabilizer, using a tetracycline-inducible expression system in human sarcoma cells (SaOs-2) that lack both functional retinoblastoma protein and p53. Paclitaxel 73-83 cyclin dependent kinase inhibitor 1A Homo sapiens 44-52 10347252-3 1999 Upon p21(waf1) induction by tetracycline withdrawal, we observed a reduced apoptotic response to paclitaxel with a 3- to 6-fold increase in IC50 values compared with that of cells not induced by p21(waf1). Paclitaxel 97-107 cyclin dependent kinase inhibitor 1A Homo sapiens 5-8 10347252-5 1999 After treatment with paclitaxel, less accumulation of G2-M was observed in p21(waf1)-induced cells compared with non-p21(waf1)-induced cells (57% versus 74%). Paclitaxel 21-31 cyclin dependent kinase inhibitor 1A Homo sapiens 75-78 10347252-5 1999 After treatment with paclitaxel, less accumulation of G2-M was observed in p21(waf1)-induced cells compared with non-p21(waf1)-induced cells (57% versus 74%). Paclitaxel 21-31 cyclin dependent kinase inhibitor 1A Homo sapiens 75-83 10347252-6 1999 p21(waf1) induction also inhibited the increased cyclin B1-associated kinase activity induced by paclitaxel. Paclitaxel 97-107 cyclin dependent kinase inhibitor 1A Homo sapiens 0-3 10347252-7 1999 Overexpression of p21(waf1) in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel. Paclitaxel 139-149 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 10347252-7 1999 Overexpression of p21(waf1) in SaOs-2 cells lacking both p53 and functional retinoblastoma protein may decrease the G2-M arrest induced by paclitaxel due to suppression of the S-G2 checkpoint, resulting in a decreased apoptotic response of cells to paclitaxel. Paclitaxel 249-259 cyclin dependent kinase inhibitor 1A Homo sapiens 18-21 9844631-5 1998 Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. Paclitaxel 143-148 cyclin dependent kinase inhibitor 1A Homo sapiens 94-101 9844631-5 1998 Overexpression of p185ErbB2 in MDA-MB-435 cells by transfection transcriptionally upregulates p21Cip1, which associates with p34Cdc2, inhibits Taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. Paclitaxel 235-240 cyclin dependent kinase inhibitor 1A Homo sapiens 94-101 9844631-7 1998 Therefore, p21Cip1 participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in p185ErbB2-overexpressing breast cancer cells. Paclitaxel 105-110 cyclin dependent kinase inhibitor 1A Homo sapiens 11-18 33436648-8 2021 Subsequent cDNA array analysis confirmed multiple PI3K-AKT pathway members such as AKT2, PIK3R3, CDKN1A, CCND2 and FGF2 to be upregulated in PTX-resistant cells. Paclitaxel 141-144 cyclin dependent kinase inhibitor 1A Homo sapiens 97-103 31285951-0 2019 Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma. Paclitaxel 84-94 cyclin dependent kinase inhibitor 1A Homo sapiens 69-75 31285951-8 2019 We then found that overexpression of CDKN1A, ELAVL2 or TSPAN4 in ESCC cell lines significantly promoted the resistance to PTX by inhibiting cell apoptosis. Paclitaxel 122-125 cyclin dependent kinase inhibitor 1A Homo sapiens 37-43 8763853-0 1996 The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1. Paclitaxel 19-24 cyclin dependent kinase inhibitor 1A Homo sapiens 77-90 8763853-4 1996 We examined the induction of p53 and its downstream target, p21WAF1/CIP1, by the microtubule active agents taxol and vinblastine with radiation. Paclitaxel 107-112 cyclin dependent kinase inhibitor 1A Homo sapiens 60-72 8763853-5 1996 An increase in induction of both p53 and p21 WAF1/CIP1 was demonstrated when radiation was added to either taxol or vinblastine treatment. Paclitaxel 107-112 cyclin dependent kinase inhibitor 1A Homo sapiens 41-54